Cargando…

Investigating Potential Biomarkers in Autism Spectrum Disorder

BACKGROUND: Early identification and treatment of individuals with autism spectrum disorder (ASD) improves outcomes, but specific evidence needed to individualize treatment recommendations is lacking. Biomarkers that could be routinely measured within the clinical setting could potentially transform...

Descripción completa

Detalles Bibliográficos
Autores principales: Bridgemohan, Carolyn, Cochran, David M., Howe, Yamini J., Pawlowski, Katherine, Zimmerman, Andrew W., Anderson, George M., Choueiri, Roula, Sices, Laura, Miller, Karen J., Ultmann, Monica, Helt, Jessica, Forbes, Peter W., Farfel, Laura, Brewster, Stephanie J., Frazier, Jean A., Neumeyer, Ann M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6687766/
https://www.ncbi.nlm.nih.gov/pubmed/31427932
http://dx.doi.org/10.3389/fnint.2019.00031
_version_ 1783442775400775680
author Bridgemohan, Carolyn
Cochran, David M.
Howe, Yamini J.
Pawlowski, Katherine
Zimmerman, Andrew W.
Anderson, George M.
Choueiri, Roula
Sices, Laura
Miller, Karen J.
Ultmann, Monica
Helt, Jessica
Forbes, Peter W.
Farfel, Laura
Brewster, Stephanie J.
Frazier, Jean A.
Neumeyer, Ann M.
author_facet Bridgemohan, Carolyn
Cochran, David M.
Howe, Yamini J.
Pawlowski, Katherine
Zimmerman, Andrew W.
Anderson, George M.
Choueiri, Roula
Sices, Laura
Miller, Karen J.
Ultmann, Monica
Helt, Jessica
Forbes, Peter W.
Farfel, Laura
Brewster, Stephanie J.
Frazier, Jean A.
Neumeyer, Ann M.
author_sort Bridgemohan, Carolyn
collection PubMed
description BACKGROUND: Early identification and treatment of individuals with autism spectrum disorder (ASD) improves outcomes, but specific evidence needed to individualize treatment recommendations is lacking. Biomarkers that could be routinely measured within the clinical setting could potentially transform clinical care for patients with ASD. This demonstration project employed collection of biomarker data during regular autism specialty clinical visits and explored the relationship of biomarkers with clinical ASD symptoms. METHODS: Eighty-three children with ASD, aged 5–10 years, completed a multi-site feasibility study integrating the collection of biochemical (blood serotonin, urine melatonin sulfate excretion) and clinical (head circumference, dysmorphology exam, digit ratio, cognitive and behavioral function) biomarkers during routine ASD clinic visits. Parents completed a demographic survey and the Aberrant Behavior Checklist-Community. Cognitive function was determined by record review. Data analysis utilized Wilcoxon two-sample tests and Spearman correlations. RESULTS: Participants were 82% male, 63% White, 19% Hispanic, with a broad range of functioning. Group means indicated hyperserotonemia. In a single regression analysis adjusting for race and median household income, higher income was associated with higher levels of blood serotonin and urine melatonin sulfate excretion levels (p = 0.004 and p = 0.04, respectively). Melatonin correlated negatively with age (p = 0.048) and reported neurologic problems (p = 0.02). Dysmorphic status correlated with higher reported stereotyped behavior (p = 0.02) and inappropriate speech (p = 0.04). CONCLUSION: This demonstration project employed collection of multiple biomarkers, allowed for examination of associations between biochemical and clinical measures, and identified several findings that suggest direction for future studies. This clinical research model has promise for integrative biomarker research in individuals with complex, heterogeneous neurodevelopmental disorders such as ASD.
format Online
Article
Text
id pubmed-6687766
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-66877662019-08-19 Investigating Potential Biomarkers in Autism Spectrum Disorder Bridgemohan, Carolyn Cochran, David M. Howe, Yamini J. Pawlowski, Katherine Zimmerman, Andrew W. Anderson, George M. Choueiri, Roula Sices, Laura Miller, Karen J. Ultmann, Monica Helt, Jessica Forbes, Peter W. Farfel, Laura Brewster, Stephanie J. Frazier, Jean A. Neumeyer, Ann M. Front Integr Neurosci Neuroscience BACKGROUND: Early identification and treatment of individuals with autism spectrum disorder (ASD) improves outcomes, but specific evidence needed to individualize treatment recommendations is lacking. Biomarkers that could be routinely measured within the clinical setting could potentially transform clinical care for patients with ASD. This demonstration project employed collection of biomarker data during regular autism specialty clinical visits and explored the relationship of biomarkers with clinical ASD symptoms. METHODS: Eighty-three children with ASD, aged 5–10 years, completed a multi-site feasibility study integrating the collection of biochemical (blood serotonin, urine melatonin sulfate excretion) and clinical (head circumference, dysmorphology exam, digit ratio, cognitive and behavioral function) biomarkers during routine ASD clinic visits. Parents completed a demographic survey and the Aberrant Behavior Checklist-Community. Cognitive function was determined by record review. Data analysis utilized Wilcoxon two-sample tests and Spearman correlations. RESULTS: Participants were 82% male, 63% White, 19% Hispanic, with a broad range of functioning. Group means indicated hyperserotonemia. In a single regression analysis adjusting for race and median household income, higher income was associated with higher levels of blood serotonin and urine melatonin sulfate excretion levels (p = 0.004 and p = 0.04, respectively). Melatonin correlated negatively with age (p = 0.048) and reported neurologic problems (p = 0.02). Dysmorphic status correlated with higher reported stereotyped behavior (p = 0.02) and inappropriate speech (p = 0.04). CONCLUSION: This demonstration project employed collection of multiple biomarkers, allowed for examination of associations between biochemical and clinical measures, and identified several findings that suggest direction for future studies. This clinical research model has promise for integrative biomarker research in individuals with complex, heterogeneous neurodevelopmental disorders such as ASD. Frontiers Media S.A. 2019-08-02 /pmc/articles/PMC6687766/ /pubmed/31427932 http://dx.doi.org/10.3389/fnint.2019.00031 Text en Copyright © 2019 Bridgemohan, Cochran, Howe, Pawlowski, Zimmerman, Anderson, Choueiri, Sices, Miller, Ultmann, Helt, Forbes, Farfel, Brewster, Frazier and Neumeyer on behalf of the Autism Consortium Biomarkers Study Clinicians. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neuroscience
Bridgemohan, Carolyn
Cochran, David M.
Howe, Yamini J.
Pawlowski, Katherine
Zimmerman, Andrew W.
Anderson, George M.
Choueiri, Roula
Sices, Laura
Miller, Karen J.
Ultmann, Monica
Helt, Jessica
Forbes, Peter W.
Farfel, Laura
Brewster, Stephanie J.
Frazier, Jean A.
Neumeyer, Ann M.
Investigating Potential Biomarkers in Autism Spectrum Disorder
title Investigating Potential Biomarkers in Autism Spectrum Disorder
title_full Investigating Potential Biomarkers in Autism Spectrum Disorder
title_fullStr Investigating Potential Biomarkers in Autism Spectrum Disorder
title_full_unstemmed Investigating Potential Biomarkers in Autism Spectrum Disorder
title_short Investigating Potential Biomarkers in Autism Spectrum Disorder
title_sort investigating potential biomarkers in autism spectrum disorder
topic Neuroscience
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6687766/
https://www.ncbi.nlm.nih.gov/pubmed/31427932
http://dx.doi.org/10.3389/fnint.2019.00031
work_keys_str_mv AT bridgemohancarolyn investigatingpotentialbiomarkersinautismspectrumdisorder
AT cochrandavidm investigatingpotentialbiomarkersinautismspectrumdisorder
AT howeyaminij investigatingpotentialbiomarkersinautismspectrumdisorder
AT pawlowskikatherine investigatingpotentialbiomarkersinautismspectrumdisorder
AT zimmermanandreww investigatingpotentialbiomarkersinautismspectrumdisorder
AT andersongeorgem investigatingpotentialbiomarkersinautismspectrumdisorder
AT choueiriroula investigatingpotentialbiomarkersinautismspectrumdisorder
AT siceslaura investigatingpotentialbiomarkersinautismspectrumdisorder
AT millerkarenj investigatingpotentialbiomarkersinautismspectrumdisorder
AT ultmannmonica investigatingpotentialbiomarkersinautismspectrumdisorder
AT heltjessica investigatingpotentialbiomarkersinautismspectrumdisorder
AT forbespeterw investigatingpotentialbiomarkersinautismspectrumdisorder
AT farfellaura investigatingpotentialbiomarkersinautismspectrumdisorder
AT brewsterstephaniej investigatingpotentialbiomarkersinautismspectrumdisorder
AT frazierjeana investigatingpotentialbiomarkersinautismspectrumdisorder
AT neumeyerannm investigatingpotentialbiomarkersinautismspectrumdisorder